Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity.

Obesity is associated with increased cardiovascular morbidity and mortality and with elevated circulating levels of the satiety factor leptin. This study provides evidence for a direct link between leptin and the risk for thrombotic complications in obese individuals. For example, although arterial injury provokes thrombosis in both lean and obese (ob/ob) mice, the time to complete thrombotic occlusion is significantly delayed in the ob/ob mice, and the thrombi formed are unstable and frequently embolize. The ob/ob mice lack leptin, and intraperitoneal administration of leptin to these mice before injury restores the phenotype of lean mice by shortening the time to occlusion, stabilizing the thrombi, and decreasing the patency rate. The thrombi that form when leptin receptor-deficient obese (db/db) mice are injured also are unstable. However, in this instance, leptin has no effect. Platelets express the leptin receptor, and leptin potentiates the aggregation of platelets from ob/ob but not db/db mice in response to known agonists. These results reveal a novel receptor-dependent effect of leptin on platelet function and hemostasis and provide new insights into the molecular basis of cardiovascular complications in obese individuals. The results suggest that these prothrombotic properties should be considered when developing therapeutic strategies based on leptin.

[1]  V. Fuster,et al.  Coronary artery disease: pathogenesis and acute coronary syndromes. , 2001, The Mount Sinai journal of medicine, New York.

[2]  P. Carmeliet,et al.  Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis , 2001, Nature Medicine.

[3]  D. Loskutoff,et al.  Plasminogen Activator Inhibitor-1 and Its Cofactor Vitronectin Stabilize Arterial Thrombi After Vascular Injury in Mice , 2001, Circulation.

[4]  P. Morange,et al.  Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. , 2000, Annals of medicine.

[5]  Thomas N. Sato,et al.  Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. , 2000, The Journal of clinical investigation.

[6]  B. Sobel,et al.  Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. , 2000, Diabetes.

[7]  A. Rao,et al.  Congenital disorders of platelet signal transduction. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[8]  Arndt F Schilling,et al.  Leptin Inhibits Bone Formation through a Hypothalamic Relay A Central Control of Bone Mass , 2000, Cell.

[9]  K. Fujioka,et al.  Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. , 1999, JAMA.

[10]  M. Laakso,et al.  Hyperglycemia and cardiovascular disease in type 2 diabetes. , 1999, Diabetes.

[11]  W. Fay,et al.  Vitronectin inhibits the thrombotic response to arterial injury in mice. , 1999, Blood.

[12]  S. Haffner,et al.  Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[13]  M. Nakata,et al.  Leptin promotes aggregation of human platelets via the long form of its receptor. , 1999, Diabetes.

[14]  J. Halaas,et al.  Leptin and the regulation of body weight in mammals , 1998, Nature.

[15]  G. Garcı́a-Cardeña,et al.  Biological action of leptin as an angiogenic factor. , 1998, Science.

[16]  Stephen R. Bloom,et al.  Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression , 1998, Nature.

[17]  D. Loskutoff,et al.  Tissue factor gene expression in the adipose tissues of obese mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Loskutoff,et al.  The adipocyte and hemostatic balance in obesity: studies of PAI-1. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[19]  S. O’Rahilly,et al.  Congenital leptin deficiency is associated with severe early-onset obesity in humans , 1997, Nature.

[20]  L. Tartaglia,et al.  The Leptin Receptor* , 1997, The Journal of Biological Chemistry.

[21]  L. Tartaglia,et al.  Leptin Receptor (OB-R) Signaling , 1997, The Journal of Biological Chemistry.

[22]  D. Loskutoff,et al.  Tissue Distribution and Regulation of Plasminogen Activator Inhibitor-1 in Obese Mice , 1996, Molecular medicine.

[23]  B. Druker,et al.  Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. , 1996, Blood.

[24]  R. Bergman,et al.  Insulin Sensitivity and Atherosclerosis , 1996 .

[25]  F. Chehab,et al.  Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin , 1996, Nature Genetics.

[26]  J. Friedman,et al.  Abnormal splicing of the leptin receptor in diabetic mice , 1996, Nature.

[27]  L. Tartaglia,et al.  Evidence That the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in db/db Mice , 1996, Cell.

[28]  R. Considine,et al.  Serum immunoreactive-leptin concentrations in normal-weight and obese humans. , 1996, The New England journal of medicine.

[29]  R. Bergman,et al.  Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. , 1996, Circulation.

[30]  Rene Devos,et al.  Identification and expression cloning of a leptin receptor, OB-R , 1995, Cell.

[31]  R. Bergman,et al.  The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. , 1995, Annals of epidemiology.

[32]  E. Ravussin,et al.  Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects , 1995, Nature Medicine.

[33]  M. Pelleymounter,et al.  Effects of the obese gene product on body weight regulation in ob/ob mice. , 1995, Science.

[34]  C. Heldin,et al.  Dimerization of cell surface receptors in signal transduction , 1995, Cell.

[35]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1995, Nature.

[36]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1994, Nature.

[37]  S. Akira,et al.  Cytokine signal transduction , 1994, Cell.

[38]  C. Schneider,et al.  The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade , 1993, Molecular and cellular biology.

[39]  P. Leder,et al.  Murine c‐mpl: a member of the hematopoietic growth factor receptor superfamily that transduces a proliferative signal. , 1993, The EMBO journal.

[40]  J. Mornon,et al.  Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Friedman,et al.  Tackling a weighty problem , 1992, Cell.

[42]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[43]  J. Fratantoni,et al.  Measuring platelet aggregation with microplate reader. A new technical approach to platelet aggregation studies. , 1990, American journal of clinical pathology.